Integrated Practices | Comprehensive Care
|
LUGPA Health Policy Alert: American Cancer Society Updates Prostate Cancer Screening Guidelines
|
Dear LUGPA Members,
The American Cancer Society (ACS) has announced a significant change to its prostate cancer screening recommendations, now encouraging routine PSA testing for average-risk men ages 50–69.
Under the updated recommendations, announced November 12, 2026:
- Average-risk men ages 50–69: ACS recommends PSA testing every two years.
- Higher-risk men: Black men and men with a strong family history of prostate cancer are encouraged to begin PSA screening at age 45, with frequency determined by individual risk.
This represents a notable shift from the previous ACS guidelines, issued in 2010, which left PSA screening for average-risk men to an individualized discussion with their physician.
Why It Matters
The updated recommendations reinforce the importance of early detection and informed prostate cancer screening. The change could help increase screening rates, identify cancers at earlier stages, and improve access to timely diagnosis and treatment. The stronger recommendation for Black men is particularly important given their disproportionate risk of dying from prostate cancer.
For urology practices, this development provides an important opportunity to engage primary care providers, educate patients, and reinforce the role of shared decision-making in prostate cancer screening.
LUGPA will continue monitoring developments in prostate cancer screening guidelines and their implications for patient access and urologic care.
Additional Resources
|
LUGPA Monthly Advocacy Update
Advancing Independent Urology Through Advocacy
|
The past few months have been a very active time for LUGPA’s advocacy efforts. We continued to advance Medicare payment reform, engage on legislative and regulatory developments affecting independent urology, and prepare for the year ahead. We also used the 2026 LUGPA Annual Meeting to highlight our advocacy accomplishments and encourage member groups to support the 2027 Advocacy Campaign.
|
Medicare Payment and Regulatory Advocacy
- Reviewed the CY 2027 Medicare Physician Fee Schedule (MPFS) Final Rule, including finalized changes to conversion factors, Modifier 25 payment, and practice expense methodology.
- Reviewed the CY 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Final Rule, including expanded ASC procedures, imaging site-neutral payment policies, and changes to 340B reimbursement.
- Continued advancing H.R. 8163/S. 5180, the Provider Reimbursement Stability Act, and H.R. 9693, the Patients First Act.
- Monitored CMS's proposed Medicare Advantage provider directory and PBM reforms and the Department of Labor's final PBM transparency rule.
Legislative Advocacy
- Reviewed the bipartisan Access to Medical Supplies Act (H.R. 10787), which would temporarily exclude customized urological and ostomy supplies from Medicare competitive bidding.
- Continued congressional and coalition advocacy for H.R. 4299, the PACT Act, ahead of the November 18 advocacy day.
- Monitored potential lame-duck opportunities to advance physician payment relief, Part B drug reimbursement reform, and prior authorization legislation.
State Advocacy
- Joined a Massachusetts coalition effort to strengthen access to biomarker testing.
- Monitored 2026 midterm election results and their implications for state legislative control and the 2027 policy landscape.
- Shared opportunities for members to engage in state advocacy through ZERO Prostate Cancer.
Member Engagement
- Highlighted LUGPA's advocacy accomplishments at the 2026 Annual Meeting, including 67 congressional office meetings across three Fly-Ins.
- Presented LUGPA's 2027 legislative and regulatory priorities.
- Launched the call for member groups to pledge their support for the 2027 Advocacy Campaign.
|
Support LUGPA’s 2027 Advocacy Campaign
|
Your Practice. Your Patients. Your Voice.
LUGPA’s advocacy is strongest when member groups participate. Congressional relationships, policy expertise, and a unified physician voice help ensure independent urology stays in the conversation as decisions are made about Medicare reimbursement, patient access, and the future of specialty care.
As LUGPA prepares for its 2027 Advocacy Campaign, we ask every member group to pledge support.
Please pledge your group’s support for LUGPA’s 2027 Advocacy Campaign
Your participation helps sustain congressional outreach, advocacy events, coalition work, and ongoing engagement with policymakers. Just as importantly, broader participation demonstrates that protecting independent urology is a shared priority across the LUGPA community.
Groups can pledge using the pledge cards distributed at the Annual Meeting or by scanning the QR code to complete the pledge online. We encourage every group to participate and to help bring more independent urology practices into the advocacy effort.
Three ways to get involved:
- Pledge: Commit your group’s support for the 2027 Advocacy Campaign.
- Participate: Join a future congressional Fly-In and share your practice’s experience with lawmakers.
- Speak up: Let LUGPA know how payment, coverage, and regulatory policies affect your practice and patients.
Every group has a role to play in protecting the future of independent urology.
Stay informed. Stay involved.
LUGPA will continue advocating for physician-led, community-based urology and the patients who depend on it. Thank you, members, for supporting these efforts and helping ensure independent urology has a strong voice in Washington and beyond.
|
Medicare & Regulatory Advocacy
|
Medicare Physician Payment Reform
LUGPA continues to advocate for a more stable and predictable Medicare physician payment system. Current payment policies do not adequately account for rising practice costs, placing continued pressure on independent practices and their ability to maintain access to community-based specialty care.
LUGPA supports advancing H.R. 8163/S. 5180, the Provider Reimbursement Stability Act, and H.R. 9693, the Patients First Act. These proposals offer potential paths toward greater payment stability, improved practice-expense calculations, and broader reform of Medicare’s physician quality reporting system.
LUGPA will continue working with Congress and physician advocacy partners to advance practical reforms that allow independent practices to remain viable and continue serving patients.
2026 Midterm Results & Lame-Duck Priorities
The 2026 midterm elections have reshaped the congressional landscape, bringing changes in congressional leadership and renewed attention to healthcare affordability, patient access, and regulatory oversight. As Congress returns for the post-election lame-duck session ahead of the December 11 government funding deadline, LUGPA remains focused on advancing the priorities of independent urology practices nationwide.
With several significant legislative items still under consideration—including government funding, healthcare program extenders, and appropriations—LUGPA is actively engaging lawmakers on both sides of the aisle to advance policies that support independent medicine. Key priorities for potential inclusion in a year-end legislative package include:
- Physician Payment Cut Relief: Securing congressional action to mitigate Medicare Physician Fee Schedule (MPFS) payment reductions and provide greater stability for physician practices.
- Medicare Part B ASP Reform (H.R. 4299): Advancing Average Sales Price (ASP) reimbursement updates to better align Medicare payments with drug acquisition costs and help preserve patient access to specialized urologic therapies.
- Prior Authorization Reform (H.R. 3514): Advancing reforms to streamline prior authorization requirements, reduce administrative burdens, and prevent unnecessary delays in patient care.
As committee assignments and leadership structures take shape for the 120th Congress, LUGPA will continue working with policymakers in both parties to champion policies that protect practice autonomy, strengthen independent medicine, and preserve access to high-quality urologic care. LUGPA will also assess opportunities to advance these priorities in the new Congress.
CY 2027 Medicare Physician Fee Schedule Final Rule
LUGPA continues to review the Centers for Medicare & Medicaid Services’ (CMS) Calendar Year (CY) 2027 Medicare Physician Fee Schedule (MPFS) Final Rule, which finalizes several policies with potential implications for independent urology practices.
Conversion Factor:
CMS finalized CY 2027 Medicare Physician Fee Schedule conversion factors of $32.95 for qualifying Advanced APM participants (QPs) and $32.63 for non-QPs. This represents decreases of 1.83% and 2.31%, respectively, compared with 2026. The reductions largely reflect the expiration of the temporary 2.5% Medicare payment increase provided for 2026, partially offset by statutory payment updates and other adjustments.
Among the changes, CMS finalized a payment reduction when a separately identifiable evaluation and management (E/M) service is furnished on the same day as a procedure with a 0-day global period. Under the final policy, the highest-valued service will be reimbursed at 100%, while the other applicable service will be reimbursed at 80%. This is narrower than the original proposal, which would have applied to procedures with 0-, 10-, and 90-day global periods and reduced payment for the additional service to 50%.
CMS also finalized changes to the practice expense methodology, including phasing out the indirect practice cost index (IPCI) over two years and introducing a new practice expense stabilizer. These changes could affect how practice expenses are allocated across specialties and individual services.
LUGPA will continue to evaluate the impact of these policies on independent urology practices and advocate for Medicare payment policies that accurately reflect the resources required to provide care in physician-led, community-based settings.
Why It Matters: Medicare payment policies directly affect the financial sustainability of independent practices and their ability to provide care in community settings. Changes to E/M reimbursement and practice expense calculations can influence practice operations, physician compensation, and the availability of office-based services. Ensuring that Medicare payment methodologies adequately recognize the costs of independent practice is essential to preserving patient access to care outside hospital-owned systems.
CY 2027 Medicare OPPS/ASC Final Rule
LUGPA is also reviewing CMS’s CY 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Final Rule, which includes several changes affecting outpatient services and independent urology practices.
CMS finalized a 2.3% payment update for hospital outpatient departments and ASCs. However, the impact on actual ASC reimbursement is less certain, as payment adjustments and the application of the ASC payment system scaler may affect the overall impact. Individual ASC results will vary depending on case mix and the services provided. The rule also removes 637 services from the Medicare Inpatient-Only (IPO) list, including procedures involving the urinary and male genital systems, allowing reimbursement in hospital outpatient settings when clinically appropriate.
CMS also finalized site-neutral payment policies for certain imaging services furnished without contrast in excepted off-campus hospital outpatient departments. Under this policy, affected services will be reimbursed at the equivalent Medicare Physician Fee Schedule rate rather than the higher OPPS rate.
Additionally, CMS finalized a reduction in Medicare reimbursement for 340B-acquired drugs from Average Sales Price (ASP) plus 6% to ASP minus 28%. This change is budget neutral and will result in an offsetting increase in OPPS payments for non-drug services. CMS also finalized a separate adjustment accelerating the recovery of prior 340B-related overpayments through a 2% annual reduction to the OPPS conversion factor for affected hospitals.
LUGPA will continue to evaluate how these policies affect independent practices, outpatient care delivery, and physicians' ability to provide services in community-based settings.
Why It Matters: Medicare outpatient payment policies influence where care is delivered and the financial incentives facing hospitals, ASCs, and independent practices. Removing additional procedures from the IPO list may create greater opportunities for outpatient surgical care, including urologic procedures. However, the impact of the ASC payment update on individual facilities remains uncertain and will depend on case mix and other payment adjustments. At the same time, site-neutral payment policies and changes to 340B reimbursement could affect hospital payment structures, competition among care settings, and patient access to community-based services.
CMS Proposes Medicare Advantage Directory and PBM Reforms
On October 16, CMS proposed a rule implementing provisions of the Consolidated Appropriations Act of 2026 addressing Medicare Advantage provider directories and pharmacy benefit manager practices.
The proposal represents another development in federal efforts to improve transparency and oversight in health care coverage and prescription drug benefit administration. LUGPA is reviewing the proposed provisions to assess their potential implications for independent urology practices, provider participation, and patient access to medications.
Why It Matters: Accurate provider information and transparent pharmacy benefit practices are important to helping patients find participating physicians and obtain prescribed treatments. LUGPA will continue monitoring the proposal and evaluating opportunities to support policies that reduce unnecessary barriers to care.
Department of Labor Finalizes PBM Transparency Requirements
On October 29, 2026, the U.S. Department of Labor (DOL) finalized its rule, Improving Transparency into Pharmacy Benefit Manager Fee Disclosure, implementing enhanced disclosure requirements under the Employee Retirement Income Security Act (ERISA). The rule requires pharmacy benefit managers (PBMs) working with certain employer-sponsored health plans to disclose direct and indirect compensation, including manufacturer rebates, administrative fees, spread pricing, and other payments. It also provides plan fiduciaries with greater access to compensation information and audit rights.
Why It Matters: Greater transparency could help employers and health plan fiduciaries evaluate PBM contracts, identify financial incentives affecting drug pricing and formulary decisions, and assess compensation arrangements. For LUGPA members, the most direct implications involve larger practices sponsoring self-insured employee health plans. Although the rule does not directly change Medicare Part B drug reimbursement, it represents another federal effort to improve PBM accountability and prescription drug benefit transparency.
|
Policy Developments
Massachusetts: LUGPA Supports Expanded Access to Biomarker Testing
LUGPA signed onto a Massachusetts coalition letter led by the American Cancer Society Cancer Action Network (ACS CAN) urging lawmakers to strengthen biomarker testing provisions in pending primary care legislation, H.5630.
The letter calls for broader compromise language aligned with biomarker coverage laws already passed in 25 other states. This effort continues the national momentum behind evidence-based diagnostic access and would help more patients access testing that can guide treatment decisions and identify appropriate targeted therapies.
For independent urology practices treating patients with cancer, expanded coverage would help address barriers to biomarker testing and support more informed treatment decisions.
Midterm Election Results Summary
Early results from the November 3 midterms show Democrats winning majorities in both chambers of Congress and gaining control of at least five state legislative chambers. As of November 4, Ballotpedia reported Democratic gains in the North Carolina and Minnesota Houses, the Pennsylvania Senate, and both chambers of the Wisconsin Legislature. In Texas, Democrats flipped a U.S. Senate seat, and Democrats regained control of the State House for the first time in more than 20+ years.
As the remaining races are called, chamber control will help determine who sets committee agendas and which bills reach the floor in 2027. In states where the parties’ split control of the legislature, advocates will need to build support with leaders from both parties to move bills through both chambers.
For a state-by-state breakdown, please see Multistate General Election Results.
State Action Opportunities Through ZERO Prostate Cancer
ZERO Prostate Cancer’s state action center offers opportunities for members to participate in state advocacy efforts. Members in the following states are encouraged to review their state’s campaign and consider contacting their lawmakers through the links below:
If you or someone you know lives in one of these states, please consider taking action and sharing these opportunities with colleagues who may wish to participate.
Thank you for your continued support of LUGPA’s state advocacy efforts and for helping improve access to high-quality urologic care.
|
Legislative Advocacy
Access to Medical Supplies Act Introduced
On October 9, Reps. Greg Murphy, M.D. (R-NC), and Brad Schneider (D-IL) introduced the bipartisan Access to Medical Supplies Act (H.R. 10787). The legislation would temporarily exclude customized urological and ostomy supplies from Medicare’s Competitive Acquisition Program for durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) for five years, from 2028 through 2032.
The bill would also establish a technical expert panel and a trial project to inform future policy decisions.
LUGPA recognizes the leadership of Dr. Murphy and Rep. Schneider in addressing concerns about patient access to medical supplies. The legislation is an important step toward ensuring that Medicare payment and purchasing policies account for the individualized nature of urological care.
LUGPA is evaluating the proposal with a focus on preserving patient choice, physician-directed care, and access to the supplies patients need. Urological supplies are not always interchangeable commodities; appropriate selection and continuity of care can be essential to patient outcomes.
Why It Matters: As CMS prepares for changes to DMEPOS competitive bidding in 2028, LUGPA will continue advocating for policies that protect access to appropriate supplies and preserve the relationship between patients and their treating physicians.
Protecting Access to Cancer and Complex Therapies
LUGPA continued supporting H.R. 4299, the Protecting Patient Access to Cancer and Complex Therapies Act, which addresses access to physician-administered Part B drugs as Medicare’s drug pricing policies expand.
LUGPA is working with the broader coalition supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299) to encourage congressional action before the end of the year. The bipartisan legislation would protect patient access to physician-administered Part B drugs by preserving ASP-based reimbursement while implementing Medicare’s negotiated drug prices through a rebate mechanism. Coalition partners are developing a sign-on letter urging House leadership and the Ways and Means Committee to advance the bill. LUGPA is reviewing the draft letter and coordinating with partners to demonstrate broad stakeholder support.
The legislation remains an important part of LUGPA’s efforts to protect community-based access to complex therapies and ensure that reimbursement policies do not unintentionally restrict where patients can receive treatment.
LUGPA is continuing congressional outreach and coalition engagement to build support for the legislation. Additional advocacy opportunities are planned, including a November 18 congressional advocacy day focused on H.R. 4299.
Why It Matters: Independent urology practices provide cancer treatment and other complex therapies close to home. Policies that undermine the financial sustainability of community-based treatment can limit patient choice and shift care toward more costly settings.
|
Patient Access, Innovation & Payer Advocacy
|
Prior Authorization and Administrative Burden
LUGPA continues to monitor payer policies that affect access to urological services and treatments. This includes ongoing attention to prior authorization requirements, coverage restrictions, and other administrative practices that can delay care or divert clinical resources away from patients.
LUGPA is also tracking federal efforts to improve prior authorization processes and increase transparency around coverage decisions. The organization will continue advocating for timely determinations, clear clinical criteria, and protections against unnecessary repeat authorizations.
Drug Pricing and Innovative Urological Treatments
LUGPA continues to engage on Medicare drug pricing policies and their implications for independent practices that provide physician-administered therapies. The organization is also pursuing opportunities to improve access to innovative urological treatments and ensure reimbursement policies appropriately recognize the value of new technologies.
These efforts include continued attention to the effects of the Medicare Drug Price Negotiation Program on physician-administered therapies, as well as engagement with stakeholders on coverage and reimbursement challenges.
Why It Matters: Patients should be able to access clinically appropriate treatments without unnecessary delays or restrictions based solely on the setting in which their physician practices. LUGPA will continue working to ensure that payment and coverage policies support high-quality, patient-centered urological care.
2027 Legislative and Regulatory Priorities
LUGPA’s Health Policy Committee and Washington, D.C., advocacy team continued work on the organization’s 2027 legislative and regulatory priorities. The priorities build on LUGPA’s ongoing efforts to protect independent urology and address the policy challenges most directly affecting member practices and their patients.
Key areas of focus include:
- Medicare Payment Reform: Advance predictable physician payment updates and meaningful Medicare payment system reform.
- Site-Neutral Payment and Community-Based Care: Address payment disparities that incentivize unnecessary hospital consolidation and support access to physician-led care.
- Patient Access to Medications and Treatments: Protect access to physician-administered therapies, specialty medications, and innovative urological treatments.
- Prior Authorization Reform: Reduce unnecessary administrative burdens and improve the timeliness and transparency of coverage decisions.
- 340B and Fair Competition: Promote appropriate oversight and accountability while preserving access to care and the resources practices need to serve patients.
- Evidence-Based Innovation: Support policies that facilitate access to effective new technologies, diagnostics, and treatments.
These priorities will guide LUGPA’s engagement with Congress, federal agencies, coalition partners, and other stakeholders throughout the coming year.
2026 LUGPA Annual Meeting: Health Policy & Advocacy
At the 2026 LUGPA Annual Meeting, LUGPA’s federal advocacy team reviewed the organization’s work in Washington, key policy challenges facing independent urology, and priorities for 2027.
2026 Advocacy in Action
LUGPA met with 67 congressional offices across three Fly-Ins in May, July, and September, building relationships with lawmakers and advocating for policies that support independent urology. Discussions focused on Medicare physician payment reform, prior authorization, access to cancer and complex therapies, site-neutral payment, and 340B reform.
2026 Midterm Elections, Federal Advocacy Priorities & State Advocacy Update
LUGPA’s Annual Meeting advocacy presentation examined how the 2026 midterm elections will shape the healthcare policy landscape and the organization’s federal and state advocacy priorities heading into 2027. The presentation covered the changing congressional landscape, potential lame-duck legislation, and emerging Democratic healthcare priorities, including Medicare payment reform, drug pricing, prior authorization, and increased industry oversight.
LUGPA’s federal advocacy efforts remain focused on addressing Medicare physician payment challenges, advancing prior authorization reform, protecting access to cancer and complex therapies, and supporting 340B accountability and site-neutral payment policies. The presentation also reviewed the status of key legislation, including the Provider Reimbursement Stability Act (H.R. 8163), Patients First Act (H.R. 9693), Improving Seniors’ Timely Access to Care Act (H.R. 3514), and Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299).
The presentation also provided an update on the CY 2027 Medicare Physician Fee Schedule and OPPS/ASC Final Rules, highlighting changes to Modifier 25, practice expense methodology, 340B drug reimbursement, site-neutral payments, and ASC reimbursement.
At the state level, LUGPA introduced its new advocacy campaign, which has tracked 60 unique bills across the states, with eight enacted or signed into law and 15 remaining active. Priorities include monitoring legislation addressing prior authorization, PBM practices, 340B, biomarker testing, and scope of practice. LUGPA will continue expanding state-level monitoring and engaging member practices to identify emerging policy issues and opportunities for advocacy.
View the Annual Meeting Health Policy & Advocacy presentation
|
Share Your Story — Amplify the Voice of Urology
|
Have reimbursement issues, administrative burden, patient access, workforce challenges, or sustainability affected your practice?
LUGPA is renewing its call for member stories to strengthen our advocacy at the federal and state levels. Policymakers respond to real-world impact, and your experiences with the Medicare Physician Fee Schedule, MACRA, prior authorization, step therapy, telehealth, workforce shortages, genetic testing, and other coverage and reimbursement challenges bring urgency and credibility to our message.
Personal stories from physicians and patients help humanize the data, influence legislative conversations, and build support among local lawmakers. Whether you submit a brief written account or record a short video, your perspective can directly shape policy discussions affecting independent urology.
Members may also record stories at upcoming LUGPA meetings as part of our expanded advocacy outreach.
To participate, submit your story to Matthew Glans. Please ensure all shared patient information complies with HIPAA requirements and includes appropriate consent.
Your voice matters, and together, we can ensure independent urology is heard loud and clear.
|
LUGPA | 875 N. Michigan Avenue, Suite 3100, Chicago, IL 60611
Catch up on LUGPA's activities and make the most of your membership by visiting us online at www.lugpa.org
|
|
|